---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-051336"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:42:04.969674+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets

## Summary
- Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.
- Trading suspended on Nasdaq at open May 22, 2025; expected to trade on OTC Markets under PTPI.
- Company has 15 days to appeal to Nasdaq Listing Council; appeal stays Form 25 but not suspension.
- No assurance that Listing Council will grant continued listing on Nasdaq.

## SEC filing metadata
- accession: 0001104659-25-051336
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465925051336/0001104659-25-051336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465925051336/tm2515781d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-051336
- JSON: https://secwatch.observer/filing/0001104659-25-051336.json
- Plain text: https://secwatch.observer/filing/0001104659-25-051336.txt

## Key facts
- Listing & Compliance Notices
  Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2), 5810(c)(3)(A)(iii), 5810(d)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1), 5550(a)(2), 5810(c)(3)(A)(iii), 5810(d)
  source text: May 20, 2025, Petros Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of (i) the Company’s failure to maintain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), (ii) the Company’s failure to meet the minimum bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2), (iii) the Company’s low bid price pursuant to Nasdaq Listing Rule 5810(
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815903/000110465925051336/0001104659-25-051336-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.